Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27871468 | 0.80 | GAA (0.34) | GAA | |
| SCHEMBL28033475 | 0.78 | GAA (0.35) | GAA | |
| SCHEMBL28033474 | 0.74 | GAA (0.35) | GAA | |
| SCHEMBL8787446 | 0.73 | — | — | |
| SCHEMBL28025815 | 0.73 | GAA (0.38) | GAA | |
| SCHEMBL28732306 | 0.71 | GAA (0.34) | GAA | |
| SCHEMBL8000240 | 0.69 | ALDH1A1 (0.39) | GAA | |
| SCHEMBL7608822 | 0.68 | ALDH1A1 (0.37) | GAA | |
| SCHEMBL18672338 | 0.68 | CYP19A1 (0.38) | GAA | |
| SCHEMBL27501010 | 0.68 | GAA (0.37) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093536-A1 | Target protein of antidiabetic and novel antidiabetic insuful corresponding thereto | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1698696-A1 | TARGET PROTEIN OF ANTIDIABETIC AGENT AND NOVEL ANTIDIABETIC AGENT INSUFUL CORRESPONDING THERETO | Reverse Proteomics Research Institute Co., Ltd (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093536-A1 | Target protein of antidiabetic and novel antidiabetic insuful corresponding thereto | IGFBP4, IGF2BP1, INSRR | GAA 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.